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A B S T R A C T
Liquid biopsy can quantify and qualify cell-free (cfDNA) and tumour-derived (ctDNA) DNA fragments in the
bloodstream. CfDNA quantification and mutation analysis can be applied to diagnosis, follow-up and therapeutic
management as novel oncologic biomarkers. However, some tumor-types release a low amount of DNA into the
bloodstream, hampering diagnosis through standard liquid biopsy procedures. Several tumors, as such as brain,
kidney, prostate, and thyroid cancer, are in direct contact with other body fluids and may be alternative sources
for cfDNA and ctDNA. Non-blood sources of cfDNA/ctDNA useful as novel oncologic biomarkers include cere-
brospinal fluids, urine, sputum, saliva, pleural effusion, stool and seminal fluid. Seminal plasma cfDNA, which
can be analyzed with cost-effective procedures, may provide powerful information capable to revolutionize
prostate cancer (PCa) patient diagnosis and management. In the near future, cfDNA analysis from non-blood
biological liquids will become routine clinical practice for cancer patient diagnosis and management.
1. Introduction
Over recent decades there has been a rapid expansion of knowledge
in the field of molecular biology and biochemistry, leading to the de-
velopment of precision medicine and tailored therapies.(Lu and Liang,
2016) The understanding of oncogenic pathways and neoplastic genetic
signatures shed the conceptual basis for the development of liquid
biopsy procedures and oncological-targeted therapies. Today, im-
munohistochemical and biochemical tumor characterization are part of
the routine process to define patient diagnosis and prognosis.(Ponti
et al., 2016; Hofman et al., 2018; Ponti et al., 2018d)
The identification of new diagnostic and prognostic markers from
non-tumoral biological samples is an interesting field in continuous
evolution. Liquid biopsy procedures have been developed to identify
oncologic biomarkers in several body fluids such as blood, plasma,
cerebrospinal liquid, seminal fluid, saliva and urine.(Ulrich and
Paweletz, 2018; Stewart et al., 2018; Burgener et al., 2017) The concept
that body fluids may reveal the presence of several systemic diseases
dates back to ancient Greek and Indian history. The development of
humoral theory was attributed to Hippocrates (ca. 460–370 BCE), and
its concepts were the base of Western medicine from antiquity through
to the 19th century. “Humoral” derives from the word “humor,” which
in ancient greek means “fluid”, and health was defined as the proper
humoral balance for that individual. The most extensively studied body
fluids are blood and urine, but many other liquids, such as cere-
brospinal fluid, saliva and seminal fluids have been analyzed in order to
determine their diagnostic and prognostic potential.
An example of a routinely applied liquid biopsy for patient man-
agement is the dosage of prostate specific antigen (PSA) in the blood-
stream. However, the PSA protein is present both in healthy and in
neoplastic prostate cells and therefore has a low sensitivity and speci-
ficity for prostate cancer (PCa) diagnosis. In contrast, tumor-derived
cell-free DNA (ctDNA) based techniques are more specific and can be
applied to many body fluids in order to identify novel oncologic bio-
markers for diagnosis, prognosis and monitoring of tumor therapeutic
response.
The presence of DNA within the non-cellular fraction of peripheral
blood, termed cell-free DNA (cfDNA), was initially identified more than
50 years ago.(Ulrich and Paweletz, 2018; Stewart et al., 2018; Burgener
et al., 2017) Decades passed before cfDNA levels were found to be
elevated within the serum of cancer patients, with at least a portion of
the cfDNA being tumor-derived (ctDNA). The advantage of ctDNA
analysis from liquids other than blood is the collection of targeted in-
formation from a body fluid directly in contact with the tumor source
(eg. cerebrospinal fluid for central nervous system neoplasm). Fur-
thermore, contrary to what occurs with ctDNA in the bloodstream,
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ctDNA in other bodily fluids are not diluted and higher concentrations
of ctDNA are derived from active secretion and/or necrotic phenomena.
ctDNA harbors cancer-specific genetic and epigenetic alterations
that allow its detection and quantification using a variety of emerging
techniques. The promise of convenient non-invasive access to the
complex and dynamic molecular features of cancer through peripheral
blood has galvanized translational researchers around this topic with
compelling routes to clinical implementation, particularly in the post
-treatment surveillance setting. (Ulrich and Paweletz, 2018; Stewart
et al., 2018; Burgener et al., 2017) Although analysis methods must
contend with small quantities of ctDNA present in most patients and the
relative over-abundance of background cfDNA derived from normal
tissues, recent technical innovations have led to dramatic improve-
ments in the sensitivity of ctDNA detection. The collection of biologic
samples to isolate cfDNA is often repeatable, allowing for real-time and
dynamic monitoring of molecular changes.(Zeng et al., 2018) As a re-
sult, ever more studies are investigating the clinical utility of ctDNA for
applications in treatment response assessment,(Dawson et al., 2013)
identification of emerging resistance mechanisms,(Mok et al., 2015;
Tabernero et al., 2015) and minimal residual disease detection.(Guo
et al., 2016) In addition, ctDNA is released from multiple tumor regions,
and may thereby represent the whole molecular picture of a patient's
malignancy, potentially solving the problem of intra-tumor hetero-
geneity,(L De Mattos-Arruda et al., 2014; Leticia De Mattos-Arruda
et al., 2015; Jamal-Hanjani et al., 2016) which may lead to false-ne-
gative results and suboptimal therapy selection, and characterization of
clonal heterogeneity and selection. (Ulrich and Paweletz, 2018; Stewart
et al., 2018; Burgener et al., 2017).
In this review we explore the application of non-blood derived
ctDNA and cfDNA in the discovery of novel oncological biomarkers,
describing the existing evidence and focusing on the recent develop-
ment of seminal plasma analysis.
2. Biology of cell free DNA and cell tumoral DNA
Cell-free DNA (cfDNA) was first identified in human plasma in 1948
and is believed to be released from cells throughout the body into the
blood stream.(MANDEL and METAIS, 1948) Most cfDNA in the blood
originates from hematopoietic cells(Allam et al., 2014; Stroun et al.,
1989) however many other organs and tissues contribute to the total
amount of blood cfDNA.(Stroun et al., 2001)
The origin of cfDNA has not fully been explored, but there are many
mechanisms by which DNA gets into the circulation. Blood cfDNA
fragments of healthy individuals are primarily of lymphoid and myeloid
origin.(Anker et al., 1999) Once outside of the cell, cfDNA is steadily
degraded by nucleases, possibly with the help of macrophages(Chused
et al., 1972) and excreted into urine via the renal system.(Thierry et al.,
2016; Botezatu et al., 2000) Multiple studies have demonstrated that
the majority of cfDNAs are short molecules around 166-167bp, al-
though longer fragments also exist.(Jiang and Lo, 2016; Snyder et al.,
2016) While necrosis results in longer fragments (> 10.000 bp),
apoptosis is associated with DNA fragments of about 180bp, or multi-
ples of this length, which appear as a ladder electrophoresis pattern.
cfDNA is likely associated with nucleosomes as the length of 167 bp
corresponds approximately to the length of DNA wrapped around a
histone.(Snyder et al., 2016) In addition to cell death, neutrophils can
mediate the immune response by releasing neutrophil extracellular
traps (NETs) that can trap and kill various pathogens.(Kaplan and
Radic, 2012) These are extracellular network structures composed of
both nuclear and mitochondrial DNA fibers, which are covered by
various proteins such as histones and proteases.(Kaplan and Radic,
2012) Another way of releasing DNA into the circulation is active re-
lease of newly synthesized DNA via vesicles and lipoproteonucleotide
complexes.(Fuchs et al., 2012) Based on the appearance in the circu-
lation, cfDNA molecules can be divided into three basic categories: free
DNA fragments, vesicle-bound DNA and DNA-macromolecular
complexes.
In cancer, a portion of cfDNA originates from tumor cells, referred
to as circulating-tumor DNA (ctDNA), and can harbor specific muta-
tions corresponding to the patient's tumor. ctDNA profiling has recently
become an area of increasing clinical relevance in oncology, in parti-
cular due to advances in the sensitivity of sequencing technologies,
allowing a reliable identification of cancer mutations. Several studies
showed high concordance between individual mutations found in
ctDNA samples and tumor tissue.(Bettegowda et al., 2014) Cancer pa-
tients have much higher cfDNA concentrations (0 to> 1000mg/mL)
than healthy individuals (0–100 ng/mL) and the total amount varies
among patients with comparable cancer type and stage.(Bettegowda
et al., 2014) Direct correlations between ctDNA level and tumor
burden, stage, vascularity and therapy response have been described for
several cancers.
cfDNA can be found in plasma as well as other body fluids such as
urine, cerebral spinal fluid (CSF), pleural fluid, and saliva, among
others.(Stewart and Tsui, 2018) Depending on tumor type, different
rates of cfDNA/ctDNA have been reported in blood samples. CtDNA was
detected in over 75% of patients with advanced pancreatic, ovarian,
colorectal, bladder, gastroesophageal, breast, melanoma, hepatocel-
lular, and head and neck cancers. However, levels below 50% were
found in primary brain tumors, in kidney, prostate, and thyroid cancers,
(Bettegowda et al., 2014) and may be due to the influence other factors,
such as blood-brain barrier restriction mechanisms, inflammatory or
autoimmune processes that increase non-tumor cfDNA fraction, effec-
tively diluting the ctDNA amount. The identification of ctDNA from
biologic fluids other than blood, enables prompt diagnosis and a reli-
able genetic identification of cancer types, characterized by shedding
low concentrations of ctDNA into the blood stream. These tumors are
often in direct contact with other body fluids, such as urine, saliva,
cerebrospinal fluid, pleural effusion or seminal liquid, releasing a
considerable amount of ctDNA and creating a privileged source for non-
invasive ctDNA quantification and characterization.
3. Sources of cfDNA in oncology
3.1. cfDNA in saliva and sputum
Saliva provides good-quality genomic DNA, which is comparable to
blood as a template for genotyping.(Bahlo et al., 2010; Hu et al., 2012;
Siravegna et al., 2017) Salivary DNA has been used for the detection of
germline mutations in various screening studies, such as for breast and
brain cancers.(Dean et al., 2015; Adel Fahmideh et al., 2015) Numerous
studies have shown that sputum tumor DNA could be a promising tool
for early detection of lung cancer. Recent studies have shown proof-of-
principle for ctDNA as a biomarker in head and neck squamous cell
carcinoma (HNSCC), with both blood and saliva serving as a diagnostic
medium. In a cohort of 93 HNSCC patients, plasma or saliva samples
were collected to identify somatic mutations (TP53, PIK3CA, CDKN2A,
HRAS, NRAS) and HPV (HPV-16, -18).(Wang et al., 2015a) Tumor DNA
was detected in 76% of saliva samples (n=93) and 87% of plasma
samples (n=47) respectively, and TP53 was the most common mutant
detected (86%). Patients with oral cavity cancers were all shown to
have tumor-specific DNA in their saliva samples (100%, n=46). Saliva
was shown to be a more sensitive predictor than plasma for early stage
disease, with 100% detection in saliva versus 70% in plasma.(Wang
et al., 2015a)
3.2. cfDNA in urine
Several reports have analyzed the value of urinary cfDNA (UCF-
DNA) for the diagnosis of bladder cancer (BC).(Todenhöfer et al., 2018)
At the present time, the standard diagnostic methods for BC are cy-
stoscopy and urine cytology. However, urine cytology has poor sensi-
tivity (except for high grade tumors)(Bier et al., 2018) and, although
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flexible cystoscopy has been recently introduced, the procedure is both
invasive and uncomfortable. Therefore, there is growing interest in new
non-invasive diagnostic tools that have better sensitivity and specificity
for BC. To overcome these difficulties, several urine-based biomarkers,
such as bladder tumor antigen, nuclear matrix protein 22 (NMP22), and
fluorescence in situ hybridization (FISH), have been studied but none of
them have been able to demonstrate superiority to cystoscopy or cy-
tology.(Breen et al., 2015)
The main source of UCF-DNA is thought to be apoptotic and ne-
crotic cancer cells.(Bryzgunova and Laktionov, 2019) UCF-DNA might
be gathered as a result of renal cfDNA transport from the blood or direct
contact from urinary tracts. Most of the UCF-DNA of urinary tract
cancers patients is not derived from blood, but is rather derived directly
from tumor cells (ctDNA). Kim TW et al. demonstrated that the non-
invasive quantification of IQ motif containing GTPase activating pro-
tein 3 (IQGAP3) urinary nucleic acids (NA) could be a suitable tool for
distinguishing between BC patients and patients with non-cancer-as-
sociated hematuria.(Kim et al., 2018) In other reports, UCF-DNA pro-
filing using PCR-based detection or high throughput sequencing tech-
nology of tumor-associated genes, has been indicated as a technique to
yield promising results in bladder and PCa. Recently Christensen et al.
applied a digital droplet PCR (ddPCR) approach for the detection of
common mutations in UCF-DNA, suggesting that the levels of mutant
ctDNA in the urine of non-muscle-invasive bladder cancer (NMIBC)
patients were positively correlated with tumor stage, grade and size,
and that a high initial level of mutant urinary ctDNA was predictive of
future disease progression.(Christensen et al., 2018) In a cystectomy
patient group, high mutant UCF-DNA was able to predict future disease
recurrence, the association being more pronounced with ctDNA.
PCa represents one of the most common tumors in European men
and one of the leading causes of male cancer associated deaths.(Alberts
et al., 2015) At present, the only noninvasive approach currently used
for the diagnosis of PCa is the determination of PSA (prostate-specific
antigen) in blood, which has been shown to reduce PCa mortality.
However, the use of PSA has recently been questioned because of its
low accuracy, especially in terms of specificity.(Alberts et al., 2015; Ilic
et al., 2018) Previous studies identified UCF-DNA integrity as a po-
tentially good marker for the early diagnosis of noninvasive PCa, with
an overall diagnostic accuracy of about 80% in small patient series.
(Casadio et al., 2013; Salvi et al., 2015) UCF-DNA is easily quantifiable
in PCa patients and could prove to be an important source of bio-
markers, such as gene mutations or epigenetic modifications, that may
accurately assist in distinguishing PCa from other benign diseases of the
urogenital tract.
3.3. cfDNA in cerebrospinal fluid
Tumor-derived DNA typically constitutes a small fraction of all
cfDNA in plasma, while the proportion of such DNA in cerebrospinal
fluid (CSF) is much higher due to the lower background of normal DNA.
(Leticia De Mattos-Arruda et al., 2015; Wang et al., 2015b) Owing to
the blood–brain barrier, CSF cfDNA is unable to circulate fully within
the blood system, resulting in a limited amount of cfDNA from central
nervous system (CNS) being released into blood plasma. Thus, blood
plasma is not the best biologic liquid for the detection and character-
ization of intercranial lesions.(Pentsova et al., 2016; Pan et al., 2015; Li
et al., 2018; Yang et al., 2014; Alix-Panabières and Pantel, 2016) CSF
circulates throughout the CNS and may provide potential information
on intracranial lesions. Few studies indicated that CSF could be an
important method of liquid biopsy in patients with CNS cancers, even
though lumbar puncture is an invasive procedure that should be per-
formed only if necessary. Moreover, selected gene profiles in CSF could
be consistent with their primary tumors.(Pentsova et al., 2016; Pan
et al., 2015; Li et al., 2018; Yang et al., 2014; Alix-Panabières and
Pantel, 2016) Li YS et al. demonstrated that CSF liquid biopsy has po-
tential clinical applications for diagnosis and characterization of
leptomeningeal metastasis (LM) of non-small cell lung cancer (NSCLC)
with mutated Epidermal Growth Factor Receptor (EGFR).(Li et al.,
2018) Moreover, CSF cfDNA has a potential role in revealing dynamic
changes of the tumor burden of LM throughout treatment, and further
studies should be conducted to explore its roles in prediction and
prognosis.(Li et al., 2018)
3.4. cfDNA in stool
Colorectal cancer (CRC), a common cause of cancer-related mor-
tality worldwide, is preventable with effective screening and removal of
precursor lesions.(Berger and Ahlquist, 2012) Yet, screening efforts
have been hampered by low participation rates and by performance
limitations of the screening tools themselves. Stool DNA testing has
emerged as a biologically rational and user-friendly strategy for the
non-invasive detection of both CRC and critical precursor lesions.
(Berger and Ahlquist, 2012; Ahlquist et al., 2008; Redwood et al., 2016)
Unlike most conventional screening tools, stool DNA testing detects
proximal and distal colorectal neoplasms with higher sensitivity com-
pared to fecal immunochemical testing for hemoglobin (FIT), for the
detection of screening-relevant colorectal neoplasia (SRN). Several key
technical advances have led to increasingly accurate approaches for
stool DNA testing, including the use of a DNA preservative buffer with
stool collection, efficient target capture and amplification methods,
broadly informative multi-marker panels, and automated assay com-
ponents.(Imperiale et al., 2004, 2014; Ahlquist et al., 2008) Based on
previous studies, advanced multi-marker stool DNA tests including
methylated markers, mutation markers and an assessment of faecal
haemoglobin, have been shown to detect CRC at sensitivities of 85%
and higher and adenomas>1 cm at 60% and higher in a case-control
environment.(Berger and Ahlquist, 2012) In a large population cross-
sectional study, Imperiale et al. demonstrated that the sensitivity of the
DNA test for the detection of both CRC (92.3%) and advanced pre-
cancerous lesions (42.4%) exceeded that of FIT by an absolute differ-
ence of nearly 20 percentage points.(Imperiale et al., 2014)
3.5. CtDNA in pleural fluids
Pleural effusion is a common complication of lung cancer. The
collection of pleural effusion fluid or of bronchial washing samples with
physiological saline solutions is currently used in diagnosing cancers of
the respiratory system.(Kimura et al., 2006; Soh et al., 2006) The de-
tection of EGFR mutations in cytological samples of pleural effusion
fluid is feasible, although often difficult owing to the limited number of
cancer cells that are usually available for analysis. Kimura et al. de-
monstrated that pleural effusion cfDNA can be used to detect EGFR
mutations and that the EGFR mutation status may be a useful predictor
of the gefitinib response in patients with non-small cell lung cancer
(NSCLC).(Kimura et al., 2006) In another study, the feasibility of
identifying EGFR mutations in tumor derived DNA collected through
bronchial washings, termed cytology cell free DNA (ccfDNA), was ex-
amined.(Kawahara et al., 2015) The results demonstrated the high
sensitivity and specificity (88% and 100%, respectively) of this ap-
proach compared with the analysis of DNA from tumor tissue, sug-
gesting that activating EGFR mutations can be accurately detected in
ccfDNA. Thus, ccfDNA might be a valuable alternative to cytological
samples, although larger investigations are needed to validate this di-
agnostic approach. A limited number of studies have investigated the
diagnostic, prognostic, or predictive value of miRNAs in pleural effu-
sion fluid from patients with NSCLC.(Han et al., 2013; Wang et al.,
2012) In one study, the authors found that a signature comprising five
miRNAs in the effusion samples was predictive of the overall survival of
patients with NSCLC and malignant pleural effusion.
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3.6. CtDNA in ascites
Detection and characterization of cfDNA in ascites has only been
analyzed in one preliminary study.(Husain et al., 2017) Husain H. et al.
isolated cfDNA from ascites and demonstrated the presence of tumori-
genic copy number variations (CNVs) in cancer-associated genes in a
small series of 6 metastatic cancer patients, providing a rationale for the
study of ascites as a source of ctDNA for the comprehensive analysis of
relevant targets.(Husain et al., 2017) In addition, in their small patient
series, the ascitic cfDNA of one patient was characterized by a 15-fold
amplification of the EGFR gene in ascites cfDNA analysis, which was not
present in two separate lung biopsies of the tumor. Even though the
significance of detecting discordant alterations in primary tissue versus
blood versus ascites is unclear, the authors hypothesized that ascites
may provide important genomic information regarding an individual's
cancer that may complement and expand data obtained from tissue
biopsies.(Husain et al., 2017)
3.7. cfDNA in seminal plasma
The quantification of serum and plasma cfDNA in PCa patients has
been found to be significantly higher with respect to age-matched
healthy controls.(Ponti et al., 2018c) It has been proven that increased
levels of cfDNA are released and can be isolated from serum and plasma
in PCa patients. Further, the level of cfDNA in PCa patients was found to
be significantly higher than in benign prostatic hyperplasia (BPH) pa-
tients.(Wyatt et al., 2017; Feng et al., 2013)
It has recently been demonstrated for the first time that human
seminal fluid can be a valuable source of cfDNA for the identification of
novel oncological biomarkers. Seminal plasma cfDNA from PCa patients
is significantly more concentrated than age-matched healthy in-
dividuals, but tumor stage has been found to be independent of other
parameters, such as age at diagnosis. (Ponti et al., 2018g, e; Ponti et al.,
2018f) Fluorometric and electrophoretic assessments allow a reliable
quantification and qualification of seminal plasma cfDNA, that could be
routinely adopted for PCa screening programs. In the same study,
seminal cfDNA of PCa patients yielded higher values than those of age-
matched healthy volunteers, 1721.27 ng/μl ng/μl and 75.4 ng/μl, re-
spectively.(Ponti et al., 2018a) This allows a reliable characterization
and differentiation between a cohort of patients affected by PCa and the
age-matched control group. The aforementioned average seminal
cfDNA is notably higher than average blood cfDNA concentrations of
PCa patients, being approximately 100 times higher compared to mean
blood cfDNA values reported in literature (1.8–35 ng/μl).(Costa et al.,
2017) In another study, seminal cfDNA was compared to BPH patients,
revealing a significant difference in the concentration levels of cfDNA in
PCa and BPH patient cohorts. A possible cut-off level of 450 ng/ul
seminal cfDNA was proposed as able to discriminate between the two
distinct groups. In addition, the electrophoresis of seminal plasma
cfDNA enabled the discrimination between PCa patients and BPH or
age-matched healthy individuals, because of a distinct electrophoretic
pattern in PCa patients.
Seminal cfDNA levels are a potential clinical biomarker in early PCa
diagnosis, referring important information regarding tumor character-
ization, patient prognosis and management, for the determination of
therapeutic strategies and subsequent follow-up.
4. cfDNA and cancer patient management
There are several important applications in which liquid biopsy
might confer an advantage to patients with cancer: the potential use of
cfDNA as a biomarker include applicatyions in the diagnostic, prog-
nostic and predictive settings. Therefore, CfDNA quantification and
analysis should be included in a management strategy that considers
the patient’s clinical status, the clinical relevance of test results, and
local feasibility of the different testing methods. Liquid biopsy can be
considered at the time of initial diagnosis in all patients who need
tumor molecular profiling, but it is particularly recommended when
tumor tissue is scarce, unavailable, or a significant delay is expected in
obtaining tumor tissue.(Stewart and Tsui, 2018) CfDNA originating
from biologic samples such as blood or other biological body fluids can
be analyzed through quantitative and qualitative analysis, guiding
cancer patient management, as demonstrated in many cancer types. For
instance, in NSCLC treatment-naive patients, EGFR and ALK re-
arrangement assessment using ctDNA is currently a recommended
procedures for cancer management. (Rolfo et al., 2018; Marmarelis
et al., 2017)
Several biologic fluids are under investigation for the diagnostic,
prognostic and therapeutic value of cfDNA quantification and analysis.
UCF-DNA and scfDNA are the most striking examples of non-blood
biologic fluids, containing large amounts of cfDNA, whose quantifica-
tion has a great prognostic and therapeutic value.
Cancer is a dynamic disease and ctDNA released by tumor cells
strictly reflects the heterogeneity of both primary cancer and metas-
tases.(Stewart et al., 2018; Stewart and Tsui, 2018) In this scenario, to
improve the standard of patient care, the institution of a Molecular
Tumor Board (MTB) has been proposed in several hospitals to discuss
the best treatment option for the patient, considering molecular testing
results, including those from liquid biopsies. Some initial experiences
have been reported.(Rolfo et al., 2018; Harada et al., 2017) Rolfo et al.
created an MTB that retrospectively evaluated 141 patients, re-
commending a treatment in 78 (55%) of patients.(Rolfo et al., 2018)
The group of Harada et al. also used MTB for the selection of cancer
patients who should be advised to perform genetic testing; resulting in
the approval of 132/191 cases for NGS analysis.(Harada et al., 2017)
4.1. Measuring disease burden
The clinical utility of liquid biopsy has been explored in different
clinical phases for several tumors, from early disease detection to the
identification of prognostic factors in early stages and to the molecular
characterization of metastatic disease and eventual relapse. The pre-
sence of ctDNA itself is indicative of disease and the amount of ctDNA
can also be an indicator of the amount of disease. As previously dis-
cussed, the amount of ctDNA is correlated with tumor stage, and many
groups have observed that higher levels of ctDNA have been associated
with worse survival outcomes in patients(Lecomte et al., 2002; Gray
et al., 2015; Gautschi et al., 2007; Stewart and Tsui, 2018), and can be
used as a measure of disease burden, along with imaging studies.
Overall, ctDNA has been shown to be a better predictor of prognosis
than other tumour markers and that ctDNA concentration increase
correlates with poorer clinical and radiological outcomes.
In CRC patients and in PCa patients, those with higher ctDNA levels
for selected genes had worse outcomes with respect to those with lower
ctDNA levels.(Romanel et al., 2015) While this observation is probably
due to the correlation between ctDNA levels and tumor burden, the
ability of cancer cells to shed DNA in circulation may also reflect dis-
ease aggressiveness.
4.2. Patient stratification and prediction of therapeutic response
Identifying molecular biomarkers in early tumor patients is needed
in order to develop more personalized follow-up and treatment sche-
dules. Detection of gene mutations in liquid biopsy for early detection
of recurrence requires highly sensitive techniques. Molecular profiling
tests prior to treatment provides the possibility of stratifying patients
based on prognosis for the administration of adjuvant therapy(Romanel
et al., 2015; Scherer et al., 2016) or for the selection of specific targeted
therapies. By measuring several mutations, either in blood or in other
body fluids, the changes in their ratios can provide some insight into the
tumor's evolution and continued heterogeneity during treatment.
(Misale et al., 2012; Chabon et al., 2016) This can also be extended to
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identify the appearance of resistance mechanisms. Serial studies of CRC
found positive selection of blood KRAS mutations during anti-EGFR
therapy and a decline in their representation after withdrawal.(Misale
et al., 2012) Similar results have been recorded in NSCLC patients
treated with EGFR inhibitors, where resistance mutations were identi-
fied in ctDNA prior to clinical progression.(Sorensen et al., 2014) A 54-
gene panel detected ctDNA in 58% of patients with multiple types of
cancer, with 68% of those having an actionable mutation by an FDA-
approved drug.(Schwaederle et al., 2016) Interestingly, DNA derived
from NSCLC tumors can be detected with high sensitivity in urine and
plasma, enabling diagnostic detection and monitoring of therapeutic
responses from non-blood body fluids.(Reckamp et al., 2016)
ctDNA has also been shown to be relevant to predict recurrence
after resection of locally advanced rectal cancer or liver metastases
from CRC.(Parkinson et al., 2016) Overman et al. showed that post-
operative detection of ctDNA was significantly correlated with relapse-
free survival (RFS). Tie et al. showed that ctDNA analysis appears to be
strongly predictive of recurrence among patients with both lower (pa-
thological complete response) and higher risk (node positive) disease.
(Parkinson et al., 2016) In this context, ctDNA could be exploited to
closely monitor patients before and after surgery to identify high-risk
patients for disease recurrence.
5. Future directions: potential non-invasive sources of DNA in
clinical pathology and oncology: Oral mucosa and skin
Guthrie/FTA card-based blood spots, buccal scrapes, and finger nail
clippings are DNA-containing specimens that are uniquely accessible
and thus attractive as alternative tissue sources.(Klassen et al., 2012) As
an alternative source to blood or buccal swabs, or both, there have been
many trials to discover a non-invasive method to collect DNA reference
samples from various specimens of the human body, such as nails, hair
and skin scales.(Hogervorst et al., 2014; Blumenberg, 2012; Bond,
2007; Ghatak et al., 2013; Albujja et al., 2018) The value of DNA
profiling from skin or adnexal samples has been previously analyzed
and reviewed for forensic purposes only and crime scene investigations,
however the application of these DNA analysis methods to skin on-
cology may allow direct genomic tumor profiling from tumor derived
skin scales, nail clippings of nail tumors or hair sampled from the tu-
moral skin surface.
Previous trials have attempted to overcome the disadvantages of
traditional samples (eg. blood samples) with the advantages of new, less
invasive sampling materials to ensure the largest possible inclusion of
subjects or volunteers in the studies. In particular, some attempts have
been made to collect reference samples from skin surface cells (Zamir
et al., 2004; Kopka et al., 2011) supporting this methodology as easy
and simple in an accessible area. Such a method could be extremely
useful among certain cultures (e.g., in the Middle East), where the use
of traditional samples or buccal swabs can be considered invasive or is
otherwise socially unacceptable. Skin lifts are a promising source of
non-blood tumoral DNA. In previously mentioned studies, all the ge-
netic profiles generated from skin lifts and swabs were consistent with
their corresponding buccal swab and blood samples, indicating that
both body regions and recovery methods yield accurate profiles (Zamir
et al., 2004; Kopka et al., 2011). The accuracy of these newer techni-
ques is necessary for future evaluations of the diagnostic value of the
tumoral DNA recovered from alternative non-blood sources.
6. Conclusion
Applications of liquid biopsies in oncology have emerged and de-
veloped at an incredible rate over the past 5 years. Many studies have
shown that cfDNA quantification is able to improve cancer diagnosis
and patient management, however, several tumor-types, as such as
kidney, prostate, and thyroid cancer, shed a low amount of cfDNA into
the bloodstream hampering the diagnosis through standard liquid
biopsy procedures. Research on cfDNA quantification from other body
fluids is a promising field for the identification of new biomarkers that
will allow prompt diagnosis and a better management of cancer pa-
tients. The current authors recently demonstrated, for the first time,
that human seminal fluid can be a valuable source of cfDNA for the
identification of novel oncological biomarkers and seminal plasma
cfDNA from PCa patients is significantly more concentrated than age-
matched healthy individuals and patients affected by BPH.(Ponti et al.,
2018e)
In the near future, the quantification and analysis of cfDNA will
probably become part of routine diagnostic and clinical management of
cancer patients. In order to accomplish this goal, it will be important to
standardize ctDNA quantification methods and allow ctDNA detection
for rare molecular alterations in order to anticipate drug resistance.
References
Adel Fahmideh, Maral, Lavebratt, Catharina, Schüz, Joachim, Röösli, Martin, Tynes, Tore,
Grotzer, Michael A., Johansen, Christoffer, et al., 2015. CCDC26, CDKN2BAS, RTEL1
and TERT polymorphisms in pediatric brain tumor susceptibility. Carcinogenesis 36
(8), 876–882. https://doi.org/10.1093/carcin/bgv074.
Ahlquist, David A., Sargent, Daniel J., Loprinzi, Charles L., Levin, Theodore R., Rex,
Douglas K., Ahnen, Dennis J., Knigge, Kandice, et al., 2008. Stool DNA and occult
blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149 (7),
441–450. W81. http://www.ncbi.nlm.nih.gov/pubmed/18838724.
Alberts, Arnout R., Schoots, Ivo G., Roobol, Monique J., 2015. Prostate-specific antigen-
based prostate Cancer screening: past and future. Int. J. Urol. 22 (6), 524–532.
https://doi.org/10.1111/iju.12750.
Albujja, Mohammed H., Dukhyil, Abdul Aziz Bin, Chaudhary, Abdul Rauf, Kassab, Ahmed
Ch, Refaat, Ahmed M., Babu, Saranya Ramesh, Okla, Mohammad K., Kumar, Sachil,
2018. Evaluation of skin surface as an alternative source of reference DNA samples: a
pilot study. J. Forensic Sci. 63 (1), 227–233. https://doi.org/10.1111/1556-4029.
13468.
Alix-Panabières, Catherine, Pantel, Klaus, 2016. Clinical applications of circulating tumor
cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6 (5), 479–491.
https://doi.org/10.1158/2159-8290.CD-15-1483.
Allam, Ramanjaneyulu, Kumar, Santhosh V.R., Darisipudi, Murthy N., Anders, Hans-
Joachim, 2014. Extracellular histones in tissue injury and inflammation. J. Mol. Med.
(Berlin, Germany) 92 (5), 465–472. https://doi.org/10.1007/s00109-014-1148-z.
Anker, P., Mulcahy, H., Chen, X.Q., Stroun, M., 1999. Detection of circulating tumour
DNA in the blood (Plasma/Serum) of Cancer patients. Cancer Metastasis Rev. 18 (1),
65–73. http://www.ncbi.nlm.nih.gov/pubmed/10505546.
Bahlo, Melanie, Stankovich, Jim, Danoy, Patrick, Hickey, Peter F., Taylor, Bruce V.,
Browning, Sharon R., Australian and New Zealand Multiple Sclerosis Genetics
Consortium (ANZgene), Brown, Matthew A., Rubio, Justin P., 2010. Saliva-derived
DNA performs well in large-scale, high-density single-nucleotide polymorphism mi-
croarray studies. Cancer Epidemiol. Biomark. Prev. 19 (3), 794–798. https://doi.org/
10.1158/1055-9965.EPI-09-0812.
Berger, Barry M., Ahlquist, David A., 2012. Stool DNA screening for colorectal neoplasia:
biological and technical basis for high detection rates. Pathology 44 (2), 80–88.
https://doi.org/10.1097/PAT.0b013e3283502fdf.
Bettegowda, Chetan, Sausen, Mark, Leary, Rebecca J., Kinde, Isaac, Wang, Yuxuan,
Agrawal, Nishant, Bartlett, Bjarne R., et al., 2014. Detection of circulating tumor DNA
in early- and late-stage human malignancies. Sci. Transl. Med. 6 (224), 224ra24.
https://doi.org/10.1126/scitranslmed.3007094.
Bier, Simone, Hennenlotter, J.örg, Esser, Michael, Mohrhardt, Sarah, Rausch, Steffen,
Schwentner, Christian, Maas, Moritz, et al., 2018. Performance of Urinary Markers
for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More
Accurate than Urine from the Bladder? Dis. Markers 2018, 1–5. https://doi.org/10.
1155/2018/5823870.
Blumenberg, Miroslav, 2012. SKINOMICS: transcriptional profiling in dermatology and
skin biology. Curr. Genomics 13 (5), 363–368. https://doi.org/10.2174/
138920212801619241.
Bond, John W., 2007. Value of DNA evidence in detecting crime. J. Forensic Sci. 52 (1),
128–136. https://doi.org/10.1111/j.1556-4029.2006.00323.x.
Botezatu, I., Serdyuk, O., Potapova, G., Shelepov, V., Alechina, R., Molyaka, Y., Ananév,
V., et al., 2000. Genetic analysis of DNA excreted in urine: a new approach for de-
tecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem.
46 (8 Pt 1), 1078–1084. http://www.ncbi.nlm.nih.gov/pubmed/10926886.
Breen, Vivienne, Kasabov, Nikola, Kamat, Ashish M., Jacobson, Elsie, Suttie, James M.,
O’Sullivan, Paul J., Kavalieris, Laimonis, Darling, David G., 2015. A Holistic
Comparative Analysis of Diagnostic Tests for Urothelial Carcinoma: A Study of
Cxbladder Detect, UroVysion® FISH, NMP22® and Cytology Based on Imputation of
Multiple Datasets. BMC Med. Res. Methodol. 15 (May), 45. https://doi.org/10.1186/
s12874-015-0036-8.
Bryzgunova, O.E., Laktionov, P.P., 2019. Extracellular nucleic acids in urine: sources,
structure, diagnostic potential. n.d.. Acta Naturae 7 (3), 48–54. http://www.ncbi.
nlm.nih.gov/pubmed/26483959.
Burgener, Justin M., Rostami, Ariana, D De Carvalho, Daniel, Bratman, Scott V., 2017.
Cell-free DNA as a post-treatment surveillance strategy: current status. Semin. Oncol.
G. Ponti, et al. Critical Reviews in Oncology / Hematology 141 (2019) 36–42
40
44 (5), 330–346. https://doi.org/10.1053/j.seminoncol.2018.01.009.
Casadio, Valentina, Calistri, Daniele, Salvi, Samanta, Gunelli, Roberta, Carretta, Elisa,
Amadori, Dino, Silvestrini, Rosella, Zoli, Wainer, 2013. Urine cell-free DNA integrity
as a marker for early prostate Cancer diagnosis: a pilot study. Biomed Res. Int. 2013,
270457. https://doi.org/10.1155/2013/270457.
Chabon, Jacob J., Simmons, Andrew D., Lovejoy, Alexander F., Esfahani, Mohammad S.,
Newman, Aaron M., Haringsma, Henry J., Kurtz, David M., et al., 2016.
Corrigendum: circulating tumour DNA profiling reveals heterogeneity of EGFR in-
hibitor resistance mechanisms in lung Cancer patients. Nat. Commun. 7 (November),
13513. https://doi.org/10.1038/ncomms13513.
Christensen, Emil, Nordentoft, Iver, Vang, S.øren, Birkenkamp-Demtröder, Karin, Jensen,
J.ørgen Bjerggaard, Agerbæk, Mads, Pedersen, Jakob Skou, Dyrskjøt, Lars, 2018.
Optimized targeted sequencing of cell-free plasma DNA from bladder Cancer patients.
Sci. Rep. 8 (1), 1917. https://doi.org/10.1038/s41598-018-20282-8.
Chused, T.M., Steinberg, A.D., Talal, N., 1972. The clearance and localization of nucleic
acids by New Zealand and normal mice. Clin. Exp. Immunol. 12 (4), 465–476. http://
www.ncbi.nlm.nih.gov/pubmed/4650369.
Costa, F., Barbisan, F., Assmann, C.E., Araújo, N.K.F., R de Oliveira, A., Signori, J.P.,
Rogalski, F., Bonadiman, B., Fernandes, M.S., da Cruz, I.B.M., 2017. Seminal cell-free
DNA levels measured by PicoGreen fluorochrome are associated with sperm fertility
criteria. Zygote (Cambridge, England) 25 (2), 111–119. https://doi.org/10.1017/
S0967199416000307.
Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda,
Oscar M., Chin, Suet-Feung, Dunning, Mark J., et al., 2013. Analysis of circulating
tumor DNA to monitor metastatic breast Cancer. N. Engl. J. Med. 368 (13),
1199–1209. https://doi.org/10.1056/NEJMoa1213261.
De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H.H., Ng, C.K.Y., Nuciforo, P., Bidard,
F.-C., et al., 2014. Capturing intra-tumor genetic heterogeneity by de novo mutation
profiling of circulating cell-free tumor DNA: a proof-of-Principle. Ann. Oncol. 25 (9),
1729–1735. https://doi.org/10.1093/annonc/mdu239.
De Mattos-Arruda, Leticia, Mayor, Regina, Ng, Charlotte K.Y., Weigelt, Britta, Martínez-
Ricarte, Francisco, Torrejon, Davis, Oliveira, Mafalda, et al., 2015. Cerebrospinal
fluid-derived circulating tumour DNA better represents the genomic alterations of
brain tumours than plasma. Nat. Commun. 6 (November), 8839. https://doi.org/10.
1038/ncomms9839.
Dean, Michael, Boland, Joseph, Yeager, Meredith, Im, Kate M., Garland, Lisa, Rodriguez-
Herrera, Maria, Perez, Mylen, et al., 2015. Addressing health disparities in hispanic
breast Cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
GigaScience 4, 50. https://doi.org/10.1186/s13742-015-0088-z.
Feng, Jiang, Gang, Feng, Li, Xiao, Jin, Tang, Houbao, Huang, Yu, Cao, Guorong, Li, 2013.
Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate
Cancer from benign Prostatic Hyperplasia in patients with increased serum prostate-
specific antigen. Int. Urol. Nephrol. 45 (4), 1023–1028. https://doi.org/10.1007/
s11255-013-0491-2.
Fuchs, Tobias A., Kremer Hovinga, Johanna A., Schatzberg, Daphne, Wagner, Denisa D.,
Lämmle, Bernhard, 2012. Circulating DNA and myeloperoxidase indicate disease
activity in patients with thrombotic microangiopathies. Blood 120 (6), 1157–1164.
https://doi.org/10.1182/blood-2012-02-412197.
Gautschi, O., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P.C.,
et al., 2007. Origin and prognostic value of circulating KRAS mutations in lung
Cancer patients. Cancer Lett. 254 (2), 265–273. https://doi.org/10.1016/j.canlet.
2007.03.008.
Ghatak, Souvik, Muthukumaran, Rajendra Bose, Nachimuthu, Senthil Kumar, 2013. A
simple method of genomic DNA extraction from human samples for PCR-RFLP ana-
lysis. J. Biomol. Tech. JBT 24 (4), 224–231. https://doi.org/10.7171/jbt.13-2404-
001.
Gray, Elin S., Rizos, Helen, Reid, Anna L., Boyd, Suzanah C., Pereira, Michelle R., Lo,
Johnny, Tembe, Varsha, et al., 2015. Circulating tumor DNA to monitor treatment
response and detect acquired resistance in patients with metastatic melanoma.
Oncotarget 6 (39), 42008–42018. https://doi.org/10.18632/oncotarget.5788.
Guo, Nannan, Lou, Feng, Ma, Yongfu, Li, Jie, Yang, Bo, Chen, Wei, Ye, Hua, et al., 2016.
Circulating tumor DNA detection in lung Cancer patients before and after surgery.
Sci. Rep. 6, 33519. https://doi.org/10.1038/srep33519.
Han, Hye-Suk, Yun, Jieun, Lim, Sung-nam, Han, Joung-Ho, Ki, Hyeong Lee, Kim, Seung
Taik, Kang, Min-Ho, et al., 2013. Downregulation of cell-free MiR-198 as a diagnostic
biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int. J.
Cancer 133 (3), 645–652. https://doi.org/10.1002/ijc.28054.
Harada, Shuko, Arend, Rebecca, Dai, Qian, Levesque, Jessica A., Winokur, Thomas S.,
Guo, Rongjun, Heslin, Martin J., et al., 2017. Implementation and utilization of the
molecular tumor board to guide precision medicine. Oncotarget 8 (34),
57845–57854. https://doi.org/10.18632/oncotarget.18471.
Hofman, V.éronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève,
Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius,
Hofman, Paul, 2018. Any place for immunohistochemistry within the predictive
biomarkers of treatment in lung cancer patients? Cancers 10 (3). https://doi.org/10.
3390/cancers10030070.
Hogervorst, Janneke G.F., Godschalk, Roger W.L., Brandt, Piet Avanden, Weijenberg,
Matty P., Verhage, Bas A.J., Jonkers, Leonie, Goessens, Joy, et al., 2014. DNA from
nails for genetic analyses in large-scale epidemiologic studies. Cancer Epidemiol.
Biomark. Prev. 23 (12), 2703–2712. https://doi.org/10.1158/1055-9965.EPI-14-
0552.
Hu, Yueshan, Ehli, Erik A., Nelson, Kelly, Bohlen, Krista, Lynch, Christophina, Huizenga,
Patty, Kittlelsrud, Julie, Soundy, Timothy J., Davies, Gareth E., 2012. Genotyping
performance between saliva and blood-derived genomic DNAs on the DMET array: a
comparison. PLoS One 7 (3), e33968. https://doi.org/10.1371/journal.pone.
0033968.
Husain, Hatim, Nykin, David, Bui, Nam, Quan, Daniel, Gomez, German, Woodward,
Brian, Venkatapathy, Sumathi, et al., 2017. Cell-free DNA from Ascites and pleural
effusions: molecular insights into genomic aberrations and disease biology. Mol.
Cancer Ther. 16 (5), 948–955. https://doi.org/10.1158/1535-7163.MCT-16-0436.
Ilic, Dragan, Djulbegovic, Mia, Jung, Jae Hung, Chang Hwang, Eu, Qi, Zhou, Cleves,
Anne, Agoritsas, Thomas, Dahm, Philipp, 2018. Prostate Cancer Screening with
prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ
(September), k3519. https://doi.org/10.1136/bmj.k3519.
Imperiale, Thomas F., Ransohoff, David F., Itzkowitz, Steven H., Levin, Theodore R.,
Lavin, Philip, Lidgard, Graham P., Ahlquist, David A., Berger, Barry M., 2014.
Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370
(14), 1287–1297. https://doi.org/10.1056/NEJMoa1311194.
Imperiale, Thomas F., Ransohoff, David F., Itzkowitz, Steven H., Turnbull, Barry A., Ross,
Michael E., Colorectal Cancer Study Group, 2004. Fecal DNA versus fecal occult
blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med.
351 (26), 2704–2714. https://doi.org/10.1056/NEJMoa033403.
Jamal-Hanjani, M., Wilson, G.A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T.,
Salari, R., et al., 2016. Detection of ubiquitous and heterogeneous mutations in cell-
free DNA from patients with early-stage non-small-cell lung cancer. Ann. Oncol. 27
(5), 862–867. https://doi.org/10.1093/annonc/mdw037.
Jiang, Peiyong, Lo, Y.M.Dennis, 2016. The long and short of circulating cell-free DNA and
the ins and outs of molecular diagnostics. Trends Genet. TIG 32 (6), 360–371.
https://doi.org/10.1016/j.tig.2016.03.009.
Kaplan, Mariana J., Radic, Marko, 2012. Neutrophil extracellular traps: double-edged
swords of innate immunity. J. Immunol. (Baltimore) 189 (6), 2689–2695. https://
doi.org/10.4049/jimmunol.1201719.
Kawahara, Akihiko, Fukumitsu, Chihiro, Taira, Tomoki, Abe, Hideyuki, Takase, Yorihiko,
Murata, Kazuya, Yamaguchi, Tomohiko, et al., 2015. Epidermal growth factor re-
ceptor mutation status in cell-free DNA supernatant of bronchial washings and
brushings. Cancer Cytopathol. 123 (10), 620–628. https://doi.org/10.1002/cncy.
21583.
Kim, Won Tae, Ye, Hwan Kim, Jeong, Pildu, Seo, Sung-Pil, Kang, Ho-Won, Kim, Yong-
June, Yun, Seok Joong, et al., 2018. Urinary cell-free nucleic acid IQGAP3: a new
non-invasive diagnostic marker for bladder cancer. Oncotarget 9 (18), 14354–14365.
https://doi.org/10.18632/oncotarget.24436.
Kimura, H., Fujiwara, Y., Sone, T., Kunitoh, H., Tamura, T., Kasahara, K., Nishio, K.,
2006. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a
practical basis for predicting the response to gefitinib. Br. J. Cancer 95 (10),
1390–1395. https://doi.org/10.1038/sj.bjc.6603428.
Klassen, Tara L., Rüden, Eva-Lottavon, Drabek, Janice, Noebels, Jeffrey L., Goldman,
Alica M., 2012. Comparative analytical utility of DNA derived from alternative
human specimens for molecular autopsy and diagnostics. J. Mol. Diagn. JMD 14 (5),
451–457. https://doi.org/10.1016/j.jmoldx.2012.04.005.
Kopka, Julieta, Leder, Monika, Jaureguiberry, Stella M., Brem, Gottfried, Boselli, Gabriel
O., 2011. New optimized DNA extraction protocol for fingerprints deposited on a
special self-adhesive security seal and other latent samples used for human identifi-
cation. J. Forensic Sci. 56 (5), 1235–1240. https://doi.org/10.1111/j.1556-4029.
2011.01853.x.
Lecomte, Thierry, Berger, Anne, Zinzindohoué, Franck, Micard, Stéphanie, Landi, Bruno,
Blons, H.élène, Beaune, Philippe, Cugnenc, Paul-Henri, Laurent-Puig, Pierre, 2002.
Detection of free-circulating tumor-associated DNA in plasma of colorectal Cancer
patients and its association with prognosis. Int. J. Cancer 100 (5), 542–548. https://
doi.org/10.1002/ijc.10526.
Li, Y.S., Jiang, B.Y., Yang, J.J., Zhang, X.C., Zhang, Z., Ye, J.Y., Zhong, W.Z., et al., 2018.
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal
metastases of EGFR-Mutant non-small-Cell lung cancer: a new medium of liquid
biopsy. Ann. Oncol. 29 (4), 945–952. https://doi.org/10.1093/annonc/mdy009.
Lu, Jun-Liang, Liang, Zhi-Yong, 2016. Circulating free DNA in the era of precision on-
cology: pre- and post-analytical concerns. Chronic Dis. Transl. Med. 2 (4), 223–230.
https://doi.org/10.1016/j.cdtm.2016.12.001.
Mandel, P., Metais, P., 1948. “[Not Available]. Comptes Rendus Des Seances de La
Societe de Biologie et de Ses Filiales 142 (3–4), 241–243. http://www.ncbi.nlm.nih.
gov/pubmed/18875018.
Marmarelis, Melina, Thompson, Jeffrey C., Aggarwal, Charu, Evans, Tracey L., Carpenter,
Erica, Cohen, Roger B., Langer, Corey J., Bauml, Joshua, 2017. Emerging uses of
circulating tumor DNA in advanced stage non-small cell lung Cancer. Ann. Transl.
Med. 5 (18), 380. https://doi.org/10.21037/atm.2017.07.29.
Misale, Sandra, Yaeger, Rona, Hobor, Sebastijan, Scala, Elisa, Janakiraman, Manickam,
Liska, David, Valtorta, Emanuele, et al., 2012. Emergence of KRAS mutations and
acquired resistance to Anti-EGFR therapy in colorectal Cancer. Nature 486 (7404),
532–536. https://doi.org/10.1038/nature11156.
Mok, Tony, Wu, Yi-Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Sandoval-Tan,
Jennifer, Ladrera, Guia, et al., 2015. Detection and dynamic changes of EGFR mu-
tations from circulating tumor DNA as a predictor of survival outcomes in NSCLC
patients treated with first-line intercalated erlotinib and chemotherapy. Clin. Cancer
Res. 21 (14), 3196–3203. https://doi.org/10.1158/1078-0432.CCR-14-2594.
Pan, Wenying, Gu, Wei, Nagpal, Seema, Gephart, Melanie Hayden, Quake, Stephen R.,
2015. Brain tumor mutations detected in cerebral spinal fluid. Clin. Chem. 61 (3),
514–522. https://doi.org/10.1373/clinchem.2014.235457.
Parkinson, Christine A., Gale, Davina, Piskorz, Anna M., Biggs, Heather, Hodgkin,
Charlotte, Addley, Helen, Freeman, Sue, et al., 2016. Exploratory analysis of TP53
mutations in circulating tumour DNA as biomarkers of treatment response for pa-
tients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS
Med. 13 (12), e1002198. https://doi.org/10.1371/journal.pmed.1002198.
Pentsova, Elena I., Shah, Ronak H., Tang, Jiabin, Boire, Adrienne, You, Daoqi, Briggs,
Samuel, Omuro, Antonio, et al., 2016. Evaluating Cancer of the central nervous
G. Ponti, et al. Critical Reviews in Oncology / Hematology 141 (2019) 36–42
41
system through next-generation sequencing of cerebrospinal fluid. J. Clin. Oncol. 34
(20), 2404–2415. https://doi.org/10.1200/JCO.2016.66.6487.
Ponti, G., Maccaferri, M., Mandrioli, M., Manfredini, M., Micali, S., Cotugno, M., Bianchi,
G., et al., 2018a. Seminal cell-free DNA assessment as a novel prostate Cancer bio-
marker. Pathol. Oncol. Res. https://doi.org/10.1007/s12253-018-0416-6.
Ponti, G., Maccaferri, M., Manfredini, M., Kaleci, S., Mandrioli, M., Pellacani, G., Ozben,
T., et al., 2018c. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop)
in the quantification of cell-free DNA (CfDNA) in malignant melanoma and prostate
Cancer patients. Clin. Chim. Acta 479. https://doi.org/10.1016/j.cca.2018.01.007.
Ponti, G., Manfredini, M., Pastorino, L., Maccaferri, M., Tomasi, A., Pellacani, G., 2018d.
PTCH1 germline mutations and the basaloid follicular hamartoma values in the
tumor Spectrum of basal cell carcinoma syndrome (NBCCS). Anticancer Res. 38 (1).
https://doi.org/10.21873/anticanres.12246.
Ponti, G., Manfredini, M., Pellacani, G., Tomasi, A., 2016. Role of Microsatellite
Instability, Immunohistochemistry and Mismatch Repair Germline Aberrations in
Immunosuppressed Transplant Patients: A Phenocopy Dilemma in Muir-Torre
Syndrome. Clin. Chem. Lab. Med. 54 (11). https://doi.org/10.1515/cclm-2015-1210.
Ponti, G., Maccaferri, M., Manfredini, M., Cotugno, M., Pellacani, G., Conti, A., Micali, S.,
Mandrioli, M., Tomasi, A., 2018e. Seminal cell-free DNA molecular profile as a novel
diagnostic and prognostic prostate cancer biomarkers. Med. Hypotheses 114 (May),
69. https://doi.org/10.1016/j.mehy.2018.02.034.
Ponti, Giovanni, Maccaferri, Monia, Mandrioli, Mauro, Manfredini, Marco, Micali,
Salvatore, Cotugno, Michele, Bianchi, Giampaolo, et al., 2018f. Seminal cell-free DNA
assessment as a novel prostate Cancer biomarker. Pathol. Oncol. Res.(May). https://
doi.org/10.1007/s12253-018-0416-6.
Ponti, Giovanni, Maccaferri, Monia, Micali, Salvatore, Manfredini, Marco, Milandri,
Riccardo, Bianchi, Giampaolo, Pellacani, Giovanni, et al., 2018g. Seminal cell free
DNA concentration levels discriminate between prostate Cancer and benign Prostatic
hyperplasia. Anticancer Res. 38 (9), 5121–5125. https://doi.org/10.21873/
anticanres.12833.
Reckamp, Karen L., Melnikova, Vladislava O., Karlovich, Chris, Sequist, Lecia V., Ross
Camidge, D., Wakelee, Heather, Perol, Maurice, et al., 2016. A highly sensitive and
quantitative test platform for detection of NSCLC EGFR mutations in urine and
plasma. J. Thorac. Oncol. 11 (10), 1690–1700. https://doi.org/10.1016/j.jtho.2016.
05.035.
Redwood, Diana G., Asay, Elvin D., Blake, Ian D., Sacco, Pamela E., Christensen, Claudia
M., Sacco, Frank D., Tiesinga, James J., et al., 2016. Stool DNA testing for screening
detection of colorectal neoplasia in Alaska Native People. Mayo Clin. Proc. 91 (1),
61–70. https://doi.org/10.1016/j.mayocp.2015.10.008.
Rolfo, Christian, Mack, Philip C., Scagliotti, Giorgio V., Baas, Paul, Barlesi, Fabrice,
Bivona, Trever G., Herbst, Roy S., et al., 2018. Liquid biopsy for advanced non-small
cell lung Cancer (NSCLC): a statement paper from the IASLC. J. Thorac. Oncol. 13 (9),
1248–1268. https://doi.org/10.1016/j.jtho.2018.05.030.
Romanel, Alessandro, Tandefelt, Delila Gasi, Conteduca, Vincenza, Jayaram, Anuradha,
Casiraghi, Nicola, Wetterskog, Daniel, Salvi, Samanta, et al., 2015. Plasma AR and
abiraterone-resistant prostate cancer. Sci. Transl. Med. 7 (312), 312re10. https://doi.
org/10.1126/scitranslmed.aac9511.
Salvi, Samanta, Gurioli, Giorgia, Martignano, Filippo, Foca, Flavia, Gunelli, Roberta,
Cicchetti, Giacomo, Giorgi, Ugo De, Zoli, Wainer, Calistri, Daniele, Casadio,
Valentina, 2015. Urine cell-free DNA integrity analysis for early detection of prostate
cancer patients. Dis. Markers 2015, 574120. https://doi.org/10.1155/2015/574120.
Scherer, Florian, Kurtz, David M., Newman, Aaron M., Stehr, Henning, Craig, Alexander
F.M., Esfahani, Mohammad Shahrokh, Lovejoy, Alexander F., et al., 2016. Distinct
biological subtypes and patterns of genome evolution in lymphoma revealed by
circulating tumor DNA. Sci. Transl. Med. 8 (364), 364ra155. https://doi.org/10.
1126/scitranslmed.aai8545.
Schwaederle, Maria, Husain, Hatim, Fanta, Paul T., Piccioni, David E., Kesari, Santosh,
Schwab, Richard B., Banks, Kimberly C., et al., 2016. Detection rate of actionable
mutations in diverse cancers using a biopsy-free (Blood) circulating tumor cell DNA
assay. Oncotarget 7 (9), 9707–9717. https://doi.org/10.18632/oncotarget.7110.
Siravegna, Giulia, Marsoni, Silvia, Siena, Salvatore, Bardelli, Alberto, 2017. Integrating
liquid biopsies into the management of Cancer. Nat. Rev. Clin. Oncol. 14 (9),
531–548. https://doi.org/10.1038/nrclinonc.2017.14.
Snyder, Matthew W., Kircher, Martin, Hill, Andrew J., Daza, Riza M., Shendure, Jay,
2016. Cell-free DNA comprises an in vivo nucleosome footprint that informs its
tissues-of-Origin. Cell 164 (1–2), 57–68. https://doi.org/10.1016/j.cell.2015.11.050.
Soh, Junichi, Toyooka, Shinichi, Aoe, Keisuke, Asano, Hiroaki, Ichihara, Syuji, Katayama,
Hideki, Hiraki, Akio, et al., 2006. Usefulness of EGFR mutation screening in pleural
fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int.
J. Cancer 119 (10), 2353–2358. https://doi.org/10.1002/ijc.22190.
Sorensen, Boe S., Wu, Lin, Wei, Wen, Tsai, Julie, Weber, Britta, Nexo, Ebba, Meldgaard,
Peter, 2014. Monitoring of epidermal growth factor receptor tyrosine kinase in-
hibitor-sensitizing and resistance mutations in the plasma DNA of patients with ad-
vanced non-small cell lung cancer during treatment with erlotinib. Cancer 120 (24),
3896–3901. https://doi.org/10.1002/cncr.28964.
Stewart, Caitlin M., Kothari, Prachi D., Mouliere, Florent, Mair, Richard, Somnay, Saira,
Benayed, Ryma, Zehir, Ahmet, et al., 2018. The value of cell-free DNA for molecular
pathology. J. Pathol. 244 (5), 616–627. https://doi.org/10.1002/path.5048.
Stewart, Caitlin M., Tsui, Dana W.Y., 2018. Circulating cell-free DNA for non-invasive
cancer management. Cancer Genet.(March). https://doi.org/10.1016/j.cancergen.
2018.02.005.
Stroun, M., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., Beljanski, M., 1989.
Neoplastic characteristics of the DNA found in the plasma of cancer patients.
Oncology 46 (5), 318–322. https://doi.org/10.1159/000226740.
Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A., Anker, P., 2001. About the possible
origin and mechanism of circulating DNA apoptosis and active DNA release. Clin.
Chim. Acta 313 (1–2), 139–142. http://www.ncbi.nlm.nih.gov/pubmed/11694251.
Tabernero, Josep, Lenz, Heinz-Josef, Siena, Salvatore, Sobrero, Alberto, Falcone, Alfredo,
Ychou, Marc, Humblet, Yves, et al., 2015. Analysis of circulating DNA and protein
biomarkers to predict the clinical activity of regorafenib and assess prognosis in
patients with metastatic colorectal Cancer: a retrospective, exploratory analysis of the
CORRECT trial. Lancet Oncol. 16 (8), 937–948. https://doi.org/10.1016/S1470-
2045(15)00138-2.
Thierry, A.R., El Messaoudi, S., Gahan, P.B., Anker, P., Stroun, M., 2016. Origins, struc-
tures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 35 (3),
347–376. https://doi.org/10.1007/s10555-016-9629-x.
Todenhöfer, Tilman, Struss, Werner J., Seiler, Roland, Wyatt, Alexander William, Black,
Peter C., 2018. Liquid biopsy-analysis of circulating tumor DNA (CtDNA) in bladder
Cancer. Bladder Cancer (Amsterdam, Netherlands) 4 (1), 19–29. https://doi.org/10.
3233/BLC-170140.
Ulrich, Bryan C., Paweletz, Cloud P., 2018. Cell-free DNA in oncology: gearing up for
clinic. Ann. Lab. Med. 38 (1), 1–8. https://doi.org/10.3343/alm.2018.38.1.1.
Wang, Tingting, Lv, Mingming, Shen, Sunan, Zhou, Sheng, Wang, Ping, Chen, Yueqiu, Liu,
Baorui, Yu, Like, Hou, Yayi, 2012. Cell-free MicroRNA expression profiles in malig-
nant effusion associated with patient survival in non-small cell lung cancer. PLoS One
7 (8), e43268. https://doi.org/10.1371/journal.pone.0043268.
Wang, Yuxuan, Springer, Simeon, Mulvey, Carolyn L., Silliman, Natalie, Schaefer, Joy,
Sausen, Mark, James, Nathan, et al., 2015a. Detection of somatic mutations and HPV
in the saliva and plasma of patients with head and neck squamous cell carcinomas.
Sci. Transl. Med. 7 (293), 293ra104. https://doi.org/10.1126/scitranslmed.aaa8507.
Wang, Yuxuan, Springer, Simeon, Zhang, Ming, Wyatt McMahon, K., Kinde, Isaac,
Dobbyn, Lisa, Ptak, Janine, et al., 2015b. Detection of tumor-derived DNA in cere-
brospinal fluid of patients with primary tumors of the brain and spinal cord. Proc.
Natl. Acad. Sci. U. S. A. 112 (31), 9704–9709. https://doi.org/10.1073/pnas.
1511694112.
Wyatt, Alexander W., Annala, Matti, Aggarwal, Rahul, Beja, Kevin, Feng, Felix, Youngren,
Jack, Foye, Adam, et al., 2017. Concordance of circulating tumor DNA and matched
metastatic tissue biopsy in prostate cancer. J. Natl. Cancer Inst. 109 (12). https://doi.
org/10.1093/jnci/djx118.
Yang, Haihong, Cai, Linbo, Zhang, Yalei, Tan, Hongyu, Deng, Qiuhua, Zhao, Meiling, Xin,
Xu., 2014. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung
adenocarcinoma patients with brain metastases. J. Mol. Diagn. 16 (5), 558–563.
https://doi.org/10.1016/j.jmoldx.2014.04.008.
Zamir, Ashira, Oz, Carla, Wolf, Ehud, Vinokurov, Asya, Glattstein, Baruch, 2004. A pos-
sible source of reference DNA from archived treated adhesive lifters. J. Forensic Sci.
49 (1), 68–70. http://www.ncbi.nlm.nih.gov/pubmed/14979346.
Zeng, Hu, He, Bo, Yi, Chengqi, Peng, Jinying, 2018. Liquid biopsies: DNA methylation
analyses in circulating cell-free DNA. J. Genet. Genomics(March). https://doi.org/10.
1016/j.jgg.2018.02.007.
G. Ponti, et al. Critical Reviews in Oncology / Hematology 141 (2019) 36–42
42
